235 East 42nd Street
New York, NY 10017
Our purpose at Pfizer is clear: Achieving breakthroughs that change patients' lives.
As one of the world's premier innovative biopharmaceutical companies, we're driven to discover the cure --driven to significantly improve the lives of everyone...everywhere. If you're similarly driven, you'll find there's no better place to begin --and continue --your career than at Pfizer.
Science is the foundation of our company. This is why it's no surprise that the most driven scientists in the world choose to carry out their life's passion at Pfizer. We arm them with the resources they need to solve some of the most complex health challenges and feared diseases of our time. Whether it's leading the way with gene therapy, using breakthrough science to transform cancer treatment, or developing novel anti-infective therapies, we're right at the cutting edge.
Join us and you'll partner with colleagues of diverse backgrounds and abilities who contribute to all aspects of what we do. Great things happen when people come together with one shared goal. If you're driven to discover the cure- ensure it has the latest technology to make it a reality or help improve the lives of others- join those who are similarly driven at Pfizer. The future of medicine is happening here.
Visit www.pfizer.com and connect with us
We look different ways. We live different ways. But at Pfizer, we share one goal. We are all…driven to discover the cure. Come and discover what we are all about.
4310 articles with Pfizer
A team of more than 60 scientists and bioethicists have signed a letter urging Pfizer to wait until late November before the company seeks FDA authorization of its COVID-19 vaccine candidate in an effort to ensure rigorous safety standards have been met.
IDEAYA and Pfizer Expand Clinical Trial Collaboration and Supply Agreement to Evaluate Clinical Combination of IDE196 and Crizotinib in Solid Tumors Harboring GNAQ or GNA11 Mutations
IDEAYA Biosciences, Inc. announced that it has expanded its clinical trial collaboration and supply agreement with Pfizer Inc. for an IDEAYA sponsored clinical combination study of IDE196, a Protein Kinase C inhibitor, and crizotinib, a cMET inhibitor to which Pfizer has exclusive worldwide rights.
Vivet Therapeutics and Pfizer Inc. Enter into Manufacturing Agreement for Vivet’s Investigational Gene Therapy for Wilson Disease
Vivet Therapeutics and Pfizer Inc. announced that they have entered into a manufacturing agreement, under which Pfizer will provide clinical supply for a Phase 1/2 clinical trial evaluating Vivet’s proprietary, investigational gene therapy, VTX-801, for the potential treatment of Wilson disease, a rare and potentially life-threatening liver disorder.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 21, 2020.
BAVENCIO Pivotal Phase III JAVELIN Bladder 100 Results Published in The New England Journal of Medicine
EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, and Pfizer Inc. announced the publication of detailed results from the Phase III JAVELIN Bladder 100 study online ahead of print in The New England Journal of Medicine.
In a weekend interview on CBS’ “Face the Nation,” Albert Bourla, chief executive officer of Pfizer indicated they may have key data from its Phase III trial of the vaccine to the U.S. Food and Drug Administration by the end of October.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 14, 2020.
Pfizer Inc. and BioNTech SE announced that they have submitted an amended protocol to the U.S. Food and Drug Administration to expand the enrollment of their Phase 3 pivotal COVID-19 vaccine trial to up to approximately 44,000 participants which also allows for the enrollment of new populations.
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference - Sep 11, 2020
Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the J.P. Morgan 11th Annual U.S. All Stars Conference on Wednesday, September 16, 2020 at 1:00 p.m. EDT.
Preclinical data for Pfizer and BioNTech’s Phase II/III COVID-19 mRNA vaccine candidate generated BNT162b2 strong anti-viral effects against an infectious SARS-CoV-2 challenge.
Pfizer and BioNTech to Potentially Supply the EU with 200 Million Doses of mRNA-based Vaccine Candidate Against SARS-CoV-2
The proposed agreement is intended to provide a supply of 200 million doses and an option to purchase additional 100 million doses, with deliveries starting by the end of 2020, subject to regulatory approval
Pfizer and BioNTech Announce Data From Preclinical Studies of mRNA-Based Vaccine Candidate Against COVID-19
Immunization of non-human primates (rhesus macaques) with BNT162b2, a nucleoside-modified messenger RNA (modRNA) candidate that expresses the SARS-CoV-2 spike glycoprotein, resulted in strong anti-viral effects against an infectious SARS-CoV-2 challenge
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 9, 2020.
The CEOs of AstraZeneca, BioNTech, GlaxoSmithKline, Johnson & Johnson, Moderna, Novavax, Pfizer, Merck and Sanofi all signed the pledge promising to ensure that any vaccine put forth by one or more of the companies meets the rigorous standards for approval.
Nine CEOs sign historic pledge to continue to make the safety and well-being of vaccinated individuals the top priority in development of the first COVID-19 vaccines
9/2/2020The U.S. government has financially backed the development of six different vaccine candidates aimed at the novel coronavirus. Although billions of dollars have been appropriated to the pandemic, at least four of those potential preventative treatments are predicted to fail in the clinic.
Parexel and Pfizer Enter Next Phase of Decade-Long PartnershipAlliance aims to speed delivery of break-through therapies to patients
Parexel, a leading provider of solutions to accelerate the development and delivery of innovative new therapies to improve world health, from Clinical through Commercialization, today announced it has signed a new master service agreement (MSA) with Pfizer Inc.
8/24/2020It was a relatively quiet week for clinical trial news. Here’s a look.
Pfizer and BioNTech Share Positive Early Data on Lead mRNA Vaccine Candidate BNT162b2 Against COVID-19
In a Phase 1 study in the U.S., at 7 days after a second dose of 30 μg, BNT162b2 elicited SARS-CoV-2–neutralizing geometric mean titers (GMTs) in younger adults (18-55 years of age) that were 3.8 times the GMT of a panel of 38 sera of SARS-CoV-2 convalescent patients, and in older adults (65-85 years of age) the vaccine candidate elicited a neutralizing GMT 1.6 times the GMT of the same panel, demonstrating strong immunogenicity in younger and older adult
Today’s data describes key safety and immunogenicity data from the U.S. Phase I study for BNT162b.